Literature DB >> 18592255

Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease.

William T Hu1, Keith A Josephs, David S Knopman, Bradley F Boeve, Dennis W Dickson, Ronald C Petersen, Joseph E Parisi.   

Abstract

TAR DNA binding protein-43 (TDP-43) immunoreactive neuronal inclusions are detected in 20-30% of Alzheimer disease (AD) brains, but the distribution of this pathology has not been rigorously studied. In this report, we describe region-specific distribution and density of TDP-43 positive neuronal cytoplasmic inclusions (NCIs) in clinically demented individuals with high probability AD pathology, all with Braak neurofibrillary tangle stages of V or VI. Sections of hippocampus, amygdala, as well as temporal, frontal, and parietal neocortex, were analyzed with TDP-43 immunohistochemistry, and the density of NCIs was assessed using a semiquantitative scoring method. Of the 29 cases, six had TDP-43 positive NCIs in the amygdala only and seven had TDP-43 inclusions restricted to amygdala and hippocampus. In 16 cases, TDP-43 immunoreactivity was more widespread, affecting temporal, frontal or parietal neocortex. These findings indicate that medial temporal lobe limbic structures are vulnerable to TDP-43 pathology in advanced AD, and that the amygdala appears to be the most susceptible region. The distribution of the lesions in this cross-sectional analysis may suggest a progression of TDP-43 pathology in AD, with limbic structures in the medial temporal lobe affected first, followed by higher order association cortices.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18592255      PMCID: PMC3404722          DOI: 10.1007/s00401-008-0400-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  26 in total

1.  Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia.

Authors:  G Wightman; V E Anderson; J Martin; M Swash; B H Anderton; D Neary; D Mann; P Luthert; P N Leigh
Journal:  Neurosci Lett       Date:  1992-05-25       Impact factor: 3.046

2.  Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.

Authors:  Deepak M Sampathu; Manuela Neumann; Linda K Kwong; Thomas T Chou; Matthew Micsenyi; Adam Truax; Jennifer Bruce; Murray Grossman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

3.  Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease.

Authors:  B T Hyman; J Q Trojanowski
Journal:  J Neuropathol Exp Neurol       Date:  1997-10       Impact factor: 3.685

4.  Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.

Authors:  Hirotake Uchikado; Wen-Lang Lin; Michael W DeLucia; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2006-07       Impact factor: 3.685

5.  Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?

Authors:  K Kosaka; M Yoshimura; K Ikeda; H Budka
Journal:  Clin Neuropathol       Date:  1984 Sep-Oct       Impact factor: 1.368

6.  Presenile dementia with motor neuron disease in Japan: clinico-pathological review of 26 cases.

Authors:  Y Mitsuyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-09       Impact factor: 10.154

7.  Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP.

Authors:  K A Josephs; R C Petersen; D S Knopman; B F Boeve; J L Whitwell; J R Duffy; J E Parisi; D W Dickson
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

8.  Ubiquitin immunohistochemistry of frontotemporal lobar degeneration differentiates cases with and without motor neuron disease.

Authors:  Omi Katsuse; Dennis W Dickson
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Oct-Dec       Impact factor: 2.703

9.  Involvement of the amygdala, dentate and hippocampus in motor neuron disease.

Authors:  V E Anderson; N J Cairns; P N Leigh
Journal:  J Neurol Sci       Date:  1995-05       Impact factor: 3.181

10.  Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype.

Authors:  Ian R A Mackenzie; Atik Baborie; Stuart Pickering-Brown; Daniel Du Plessis; Evelyn Jaros; Robert H Perry; David Neary; Julie S Snowden; David M A Mann
Journal:  Acta Neuropathol       Date:  2006-09-26       Impact factor: 17.088

View more
  71 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

2.  Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models.

Authors:  Alexander M Herman; Preeti J Khandelwal; G William Rebeck; Charbel E-H Moussa
Journal:  Exp Neurol       Date:  2012-02-28       Impact factor: 5.330

Review 3.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

4.  TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy.

Authors:  Ann C McKee; Brandon E Gavett; Robert A Stern; Christopher J Nowinski; Robert C Cantu; Neil W Kowall; Daniel P Perl; E Tessa Hedley-Whyte; Bruce Price; Chris Sullivan; Peter Morin; Hyo-Soon Lee; Caroline A Kubilus; Daniel H Daneshvar; Megan Wulff; Andrew E Budson
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

5.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

6.  Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-05-02       Impact factor: 21.566

7.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

8.  Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome.

Authors:  Carol F Lippa; Andrea L Rosso; Lauren D Stutzbach; Manuela Neumann; Virginia M-Y Lee; John Q Trojanowski
Journal:  Arch Neurol       Date:  2009-12

9.  In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.

Authors:  Veronika Hanko; Alexandra C Apple; Kathryn I Alpert; Kristen N Warren; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Lei Wang
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

10.  TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study.

Authors:  Margaret E Flanagan; Brenna Cholerton; Caitlin S Latimer; Laura S Hemmy; Steven D Edland; Kathleen S Montine; Lon R White; Thomas J Montine
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.